It has been reported that Dox-treated cancer cells develop resistance to Dox by activating the ubiquitin-proteasome system [44,45] leading to the activation of NF-κB and DNA repair pathway, and thus Dox resistance can be antagonized by proteasome inhibitors [46,48]. This evidence concerns the gene NFKB1 and cancer.